Imaging AD Progression Amyloid Imaging Agents.

Slides:

Advertisements

Similar presentations

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.

Advertisements

Department of Neurology, Mayo Clinic Arizona

Frontotemporal Dementia

©2011 MFMER | slide-1 Alzheimer Disease: Update Neill R. Graff-Radford, MBBCh, FRCP Professor of Neurology Mayo College of Medicine.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

ADNI 3 Clinical Core Plans

CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.

Alzheimer's Disease – Current Status; Future Perspectives

Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.

Pr Bruno Dubois Head of the Dementia Research Center (IMMA)

Screening for Stroke and Cognitive Impairment Chapter 2: Background.

Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.

There are currently 26 million people worldwide with Alzheimer’s disease. This figure is projected to grow to more than 106 million people by 2050.

Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.

ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.

ROLE OF AMYLOID IMAGING IN THE REVISED CRITERIA FOR THE DIAGNOSIS OF ALZHEIMER DISEASE Serge Gauthier, MD, FRCPC McGill Center for Studies in Aging Douglas.

Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.

 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer’s is the most common form of dementia. This.

ALZHIEMERS DISEASE IN UK ‘’The Dementia Time bomb’’ By VISHAL ZAVERI AND ORE AJAI.

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

HOW TO EXAMINE PATIENTS WITH DEMENTIA Serge Gauthier, MD, FRCPC McGill Centre for Studies in Aging Douglas Mental Health Research Institute.

The Dementias Dr Giles Richards Consultant Psychiatrist CFT.

Update Arg-ADNI Instituto de Investigaciones Neurológicas (FLENI)

Epidemiology of Alzheimer’s Disease

Background. Vascular Cognitive Impairment Vascular Cognitive Impairment (VCI) includes the cognitive and behavioural disorders associated with cerebrovascular.

Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,

Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.

Alzheimer's disease 蕭尚益丁唯洋蔡欣容. Outline introductionDisease mechanismPreventConclusion.

The clinical research of early diagnosis and ultimately the treatment of Alzheimer’s disease 許一仁董冠廷詹鎮遠陳柏廷.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital.

Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.

Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.

WISCONSIN ALZHEIMER’S DISEASE RESEARCH CENTER

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease Mirjana Babić.

Volume 3, Issue 4, Pages (November 2017)

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Rosa Maria Moresco University of Milan Bicocca

Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73

Can We Treat Alzheimers 20 years early?

Presenter: Dr. Patricio Chrem

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Dementia: from molecules to minds

What will it take to develop an effective Alzheimer’s drug?

Brain Tech TIME Case Study: FDG PET IMAGING IN DEMENTIA (FTD vs AD)

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Modifying Disease Course in Alzheimer's Disease

Amyloid Imaging for Alzheimer's Disease in Practice

Early Dementia Distinguishing AD From MCI

Reisa Sperling, Elizabeth Mormino, Keith Johnson Neuron

Probing the Biology of Alzheimer's Disease in Mice

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Quantitative PET Imaging; from Research to Clinical Use

AAIC 2018 Biomarker Rates of Change in Autosomal Dominant Versus “Sporadic” Alzheimer Disease John C. Morris, MD On behalf of MW Weiner, L Beckett, T.

Presenter: Dr. Patricio Chrem

Imaging in dementia / cognitive impairment

Treating to Target in MS

Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Chris Hyde Exeter Test Group.

Argentina Arg-ADNI Ezequiel Surace, PhD.

NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease Clifford R Jack Jr MD Prof. of Radiology and Alexander Family Professor.

Biomarker Modeling of Alzheimer’s Disease

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

Fig. 2. Correlation between Aβ42 and Aβ40 levels in iNPH, AD, and CN subjects. The scatter plot shows the correlation between Aβ42 and Aβ40 levels. Representative.

Interreg-IPA Cross-border Cooperation Programme Romania-Serbia

Figure 2 Aβ-PET scans obtained using different tracers

Presentation transcript:

Imaging AD Progression

Amyloid Imaging Agents

Potential Clinical Roles for Amyloid Imaging Presented at SNMMI 2014

Longitudinal Amyloid PET in Patients With MCI

Presence of Brain Amyloid and Accelerated Cognitive Decline

Aβ Burden in People With Subjective Memory Complaints

More Complex Clinical Scenarios

Late-life Depression and Amyloid Accumulation in MCI

Post-stroke Dementia

Conclusions

Amyloid PET Imaging

Amyloid PET Tracers

A Negative Florbetaben PET Scan Reliably Excludes Amyloid Pathology as Confirmed by Histopathology

Prevalence of Aβ PET Positivity Across Dementia Syndromes

Prevalence of Aβ PET Positivity Across Dementia Syndromes (cont)

Imaging MCI With A Second-Generation Tracer

Diagnostic Value of Amyloid Imaging in Early-Onset Dementia

Amyloid PET Has Greater Clinical Impact Than FDG PET in the Differential Diagnosis of AD and FTD

Conclusions

Vascular Risk Factors Impact Cognition Independent of PiB PET and MRI Measures of AD and Vascular Brain Injury

Existing Thresholds for PiB Positivity Are Too High

Physical Activity Modifies Alzheimer Biomarkers in Preclinical AD

Imaging of Tau Pathology in Patients with Non-AD Tauopathies

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)